<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200809048341N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-11-23</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of  ketamine /propofol Versus ketamine/Thiopental in Procedural Sedational analgesia for Reduction of Anterior Shoulder Dislocation</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of  ketamine /propofol Versus ketamine/Thiopental in Procedural Sedational analgesia for Reduction of Anterior Shoulder Dislocation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-11-28</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/50629</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple individual randomization: Based on a random sequence of numbers from Random.org, a table will be prepared, with the first forty-five consecutive numbers in Group A and the next forty-five consecutive numbers in Group B.These numbers will be assigned to each patient in order of referral, Blinding description: The person performing the reduction and the patient themselves do not know the type of medicine;  For this purpose, the syringe containing the drug is covered in such a way that the color of the drug is not clear.</study_design>
      <phase>3</phase>
      <hc_freetext>Procedural Sedational analgesia for Reduction of Anterior Shoulder Dislocation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: First, we inject 30 mg of ketorolac intravenously in all patients for 30 minutes 15 minutes before prescribing other drugs.  We then inject 1 mg of midazolam intravenously into all patients.  Then from the combination of ketamine / propofol (ketamine 1 mg per kg body weight (maximum 50 mg) and propofol 1 mg per kg body weight (maximum 50 mg) intravenously and slowly for 30-60 seconds)  Used.  If sedation does not occur in this group within 3 minutes, half the dose of the first medication is repeated.  If, after injecting the initial dose, after receiving two and a half doses of the drug, proper sedation does not occur or the reduction is not successful, sedation is considered a failure and orthopedic consultation is requested.  Appropriate sedation is determined by the RASS score (Richmond Agitation and Sedation Scale);  We start reduction when the patient has a RASS score of -4.  After sedation, reduction is performed by Liddell Meyer method and Milch alternative method is considered.  In case of nausea, vomiting of ondansetron at a dose of 4 mg and in case of hypoxia, apnea or spasm, respectively, head tilt chin lift, oral airway and ambobag breathing, and if none of them were effective, intubation should be used. Intervention 2: Intervention group 2: First, all patients are injected with 30 mg of intravenous ketorolac within 30 seconds 15 minutes before prescribing other drugs.  One mg of midazolam is then injected intravenously into all patients.  The thiopental / ketamine combination is then used (ketamine 1 mg per kg body weight (maximum 50 mg) and thiopental 2 mg per kg body weight (maximum 100 mg) intravenously and slowly  Within 30-60 seconds).  If sedation does not occur in this group within 3 minutes, half the dose of the first medication is repeated.  If proper sedation does not occur after injecting the initial dose after receiving two half doses, or the reduction is not successful, failure in sedation is considered and orthopedic consultation is requested.  Appropriate sedation is determined by the  RASS score (Richmond Agitation and Sedation Scale)؛  We start reduction when the patient has a RASS score to -4. After sedation, reduction is performed by Liddell Meyer method and Milch alternative method is considered.  In case of nausea, vomiting of ondansetron at a dose of 4 mg and in case of hypoxia, apnea or , spasm, respectively, head tilt chin lift, oral airway and ambobag breathing, and if none of them were effective, intubation should be used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Hajisafari Tafti</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 9, Shamshad Alley 7, Fatemieh Blvd, Shahid Sadoughi Town</address>
        <city>Taft</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8991877685</zip>
        <telephone>+98 35 3263 5841</telephone>
        <email>Z.hajisafaritafti@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Soheila Azimi Aabarghouei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emergency ward, Shahid Sadoughi Hospital, Ebne sina Blvd.</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8913893111</zip>
        <telephone>+98 35 3828 2682</telephone>
        <email>S.azimi@ssu.ac.ir</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Healthy patients without previous disease and those with mild systemic disease without functional limitations according to the American Society of Anesthesiologist classification (individuals 1 and 2)
Those who have been NPOs ( Nil Per Os) or consumed fluids in the last 3 hours
Those that do not need to be reduced in the operating room.
Age 18 to 64 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>64 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Any contraindications including asthma and COPD(chronic obstructive pulmonary disease), systolic blood pressure below 90 or above 180, ischemic heart disease or heart failure, any symptoms in favor of increased intracranial pressure, glaucoma, psychosis and use of any psychotropic substances, acute or chronic alcoholism, liver or kidney failure,  Allergies to any of the drugs studied or eggs or soy, people addicted to drugs, taking any sedatives or anesthetics before going to the emergency room, obstructive sleep apnea syndrome, maxillofacial malformations that block the airway,  Pregnancy, dislocations lasting more than 24 hours, multiple trauma or hemodynamic instability, history of uncontrollable seizures, and patients who do not wish to participate in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S43.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Subluxation and dislocation of shoulder joint</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: First, we inject 30 mg of ketorolac intravenously in all patients for 30 minutes 15 minutes before prescribing other drugs.  We then inject 1 mg of midazolam intravenously into all patients.  Then from the combination of ketamine / propofol (ketamine 1 mg per kg body weight (maximum 50 mg) and propofol 1 mg per kg body weight (maximum 50 mg) intravenously and slowly for 30-60 seconds)  Used.  If sedation does not occur in this group within 3 minutes, half the dose of the first medication is repeated.  If, after injecting the initial dose, after receiving two and a half doses of the drug, proper sedation does not occur or the reduction is not successful, sedation is considered a failure and orthopedic consultation is requested.  Appropriate sedation is determined by the RASS score (Richmond Agitation and Sedation Scale);  We start reduction when the patient has a RASS score of -4.  After sedation, reduction is performed by Liddell Meyer method and Milch alternative method is considered.  In case of nausea, vomiting of ondansetron at a dose of 4 mg and in case of hypoxia, apnea or spasm, respectively, head tilt chin lift, oral airway and ambobag breathing, and if none of them were effective, intubation should be used.</i_keyword>
      <i_keyword>Intervention group 2: First, all patients are injected with 30 mg of intravenous ketorolac within 30 seconds 15 minutes before prescribing other drugs.  One mg of midazolam is then injected intravenously into all patients.  The thiopental / ketamine combination is then used (ketamine 1 mg per kg body weight (maximum 50 mg) and thiopental 2 mg per kg body weight (maximum 100 mg) intravenously and slowly  Within 30-60 seconds).  If sedation does not occur in this group within 3 minutes, half the dose of the first medication is repeated.  If proper sedation does not occur after injecting the initial dose after receiving two half doses, or the reduction is not successful, failure in sedation is considered and orthopedic consultation is requested.  Appropriate sedation is determined by the  RASS score (Richmond Agitation and Sedation Scale)؛  We start reduction when the patient has a RASS score to -4. After sedation, reduction is performed by Liddell Meyer method and Milch alternative method is considered.  In case of nausea, vomiting of ondansetron at a dose of 4 mg and in case of hypoxia, apnea or , spasm, respectively, head tilt chin lift, oral airway and ambobag breathing, and if none of them were effective, intubation should be used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Time to appropriate sedation. Timepoint: 3 minutes after the last drug injection. Method of measurement: physical examination.</prim_outcome>
      <prim_outcome>The duration of the effect of the drug. Timepoint: 15 minutes after drug injection. Method of measurement: Physical examination.</prim_outcome>
      <prim_outcome>Discharge time. Timepoint: 15 minutes after drug infection. Method of measurement: Physical examination.</prim_outcome>
      <prim_outcome>The pain before reduction. Timepoint: before starting  reduction. Method of measurement: By the visual analog scale.</prim_outcome>
      <prim_outcome>Need to additional doses of medication. Timepoint: 3 minutes after the last injection. Method of measurement: Physical examination.</prim_outcome>
      <prim_outcome>Incidence of any side effects. Timepoint: Before injecting the drug and every 5 minutes. Method of measurement: Physical examination and vital signs.</prim_outcome>
      <prim_outcome>Pain during reduction. Timepoint: During reduction. Method of measurement: By the facial pain scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-12</approval_date>
        <contact_name>Ethics committee of School of Medicine _ Shahid Sadoughi University of Medical Sciences</contact_name>
        <contact_address>Central building of Shahid Sadoughi University of Medical Sciences, Bahonar Square,  Yazd Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
